BioWorld

March 4, 2002

Essential Acquiring Maret For 2M Shares Of Locked-Up Stock

Essential Therapeutics Inc. on Friday said it will strengthen its clinical and preclinical pipeline through the acquisition of Maret Pharmaceuticals Inc. in a deal valued at up to about $6.8 million. (BioWorld Today) Read More

Titan Cancer Antibodies Paired In Colorectal Phase II Study

KO Mice Answer In Affirmative; Ablation Of Muc2 Gene Results In Full-Blown Colorectal Cancers

Peregrine, Oxigene End Venture On Vascular Targeting Agents

InterMune Goes To Shelf, Files To Sell 2.5M Shares

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Feb. 6, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

REST emerges as biomarker in ALS, knockdown improves ALS symptoms

BioWorld Science

About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...

Serotonin receptor modulators for the treatment of OUD

BioWorld Science

Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...

KLF15 shows potential as marker, target for cholangiocarcinoma

BioWorld Science

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...